Join The Discussion

 

Moves by Jeb Bush add to talk of 2016 candidacy

WASHINGTON — Jeb Bush's decision to release a policy-laden e-book and all his emails from his time as governor of Florida has further stoked expectations among his allies that he will launch a presidential bid.

read more >

Ebby Halliday acquires Fort Worth’s Williams Trew

Williams Trew Real Estate of Fort Worth has been acquired by Dallas-based residential real estate brokerage Ebby Halliday Real Estate Inc.

read more >

Fort Worth businessman to lead Abbott, Patrick inauguration efforts

Fort Worth businessman Ardon Moore will chair the committee running inauguration festivities for Gov.-elect Greg Abbott and Lt. Gov.-elect Dan Patrick in January, it was announced on Friday.   Moore, president of Lee M. Bass Inc. in Fort Worth, is a vice chairman of the University of Texas Investment

read more >

Meridian Bank Texas parent acquired by UMB Financial for $182.5M

Kansas City, Mo.-based UMB Financial Corp., the parent company of UMB Bank, said Dec. 15 it has signed a definitive agreement to acquire Marquette Financial Companies in an all-stock transaction.

read more >

Cousins Properties to sell 777 Main tower in downtown Fort Worth

Cousins Properties Inc. has confirmed plans to sell the 777 Main office tower in downtown Fort Worth, according to a news release from the Atlanta-based real estate investment firm.

read more >

Former TECH Fort Worth client raises $107M in IPO

ZS Pharma Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, raised nearly $107 million on the NASDAQ capital market from its initial public offering on June 18.
ZS Pharma, a Texas Emerging Technology Fund awardee based in Coppell, also granted the underwriters a 30-day option to purchase up to an additional 891,667 shares of common stock at the IPO price, less underwriting discounts and commissions. The offering is expected to close on or about June 23, subject to customary closing conditions.


ZS Pharma received a $2 million TETF award in 2010 for its development of an orally available sorbent product, ZS-9, which was designed to remove excess potassium from the blood and maintain normal potassium levels. This technology could potentially be used to treat hyperkalemia, a condition that can lead to irregular heartbeat and sudden cardiac death. ZS Pharma was a client of TECH Fort Worth.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the IPO. BMO Capital Markets Corp. is lead manager and William Blair & Co. LLC is co-manager.
ZS Pharma Inc. is traded under the symbol ZSPH.

Betty Dillard
bdillard@bizpress.net


 

< back

Email   email
hide
TCU/Baylor
Did the College Football Playoff Committee get it right?